Literature DB >> 23959272

Binding of V(IV)O²⁺ to the Fe binding sites of human serum transferrin. A theoretical study.

Gonçalo C Justino, Eugenio Garribba, João Costa Pessoa.   

Abstract

The binding of V(IV)O²⁺ to human serum transferrin (hTF) at the FeIII binding sites is addressed. Geometry optimization calculations were performed for the binding of V(IV)O²⁺ to the N-terminal lobe of hTF (hTFN), and indicate that in the presence of CO₃²⁻ or HCO₃ −, V(IV) is bound to five atoms in a distorted geometry. The structures of V(IV)O-hTFN species optimized at the semiempirical level were also used to calculate the ⁵¹V and ¹⁴N A tensors by density functional theory methods, and were compared with the reported experimental values. Globally, of all the calculated V(IV)O-hTF structures, the one that yields the lowest calculated heats of formation and minimum deviations from the experimental values of the ⁵¹V and ¹⁴N A tensor components is the structure that includes CO₃²⁻ as a synergistic anion. In this structure the V=O bond length is approximately 1.6 Å, and the vanadium atom is also coordinated to the phenolate oxygen atom of Tyr188 (at approximately 1.9 Å), the aspartate oxygen atom of Asp63 (at approximately 1.9 Å), the His249 Nτ atom (at approximately 2.1 Å), and a carbonate oxygen atom (at approximately 1.8 Å). The Tyr95 phenolic ocygen atom is approximately 3.3 Å from the metal center, and thus is very weakly bound to V(IV). All of these oxygen atoms are able to establish dipolar interactions with groups of the protein.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23959272     DOI: 10.1007/s00775-013-1029-x

Source DB:  PubMed          Journal:  J Biol Inorg Chem        ISSN: 0949-8257            Impact factor:   3.358


  47 in total

1.  New insights into the interactions of serum proteins with bis(maltolato)oxovanadium(IV): transport and biotransformation of insulin-enhancing vanadium pharmaceuticals.

Authors:  Barry D Liboiron; Katherine H Thompson; Graeme R Hanson; Edmond Lam; Nicolas Aebischer; Chris Orvig
Journal:  J Am Chem Soc       Date:  2005-04-13       Impact factor: 15.419

2.  Is the spin-orbit coupling important in the prediction of the 51V hyperfine coupling constants of V(IV) O2+ species? ORCA versus Gaussian performance and biological applications.

Authors:  Giovanni Micera; Eugenio Garribba
Journal:  J Comput Chem       Date:  2011-07-06       Impact factor: 3.376

3.  Comparison of the electron spin echo envelope modulation (ESEEM) for human lactoferrin and transferrin complexes of copper(II) and vanadyl ion.

Authors:  S S Eaton; J Dubach; K M More; G R Eaton; G Thurman; D R Ambruso
Journal:  J Biol Chem       Date:  1989-03-25       Impact factor: 5.157

4.  Simultaneous multiple element detection by particle beam/hollow cathode-optical emission spectroscopy as a tool for metallomic studies: determinations of metal binding with apo-transferrin.

Authors:  C Derrick Quarles; Julia L Brumaghim; R Kenneth Marcus
Journal:  Metallomics       Date:  2009-10-20       Impact factor: 4.526

5.  Cross-docking study on InhA inhibitors: a combination of Autodock Vina and PM6-DH2 simulations to retrieve bio-active conformations.

Authors:  Jean-Luc Stigliani; Vania Bernardes-Génisson; Jean Bernadou; Geneviève Pratviel
Journal:  Org Biomol Chem       Date:  2012-06-29       Impact factor: 3.876

6.  Vanadium(V) complexes with salicylaldehyde semicarbazone derivatives bearing in vitro anti-tumor activity toward kidney tumor cells (TK-10): crystal structure of [VVO2(5-bromosalicylaldehyde semicarbazone)].

Authors:  Pabla Noblía; Marisol Vieites; Beatriz S Parajón-Costa; Enrique J Baran; Hugo Cerecetto; Patricia Draper; Mercedes González; Oscar E Piro; Eduardo E Castellano; Amaia Azqueta; Adela López de Ceráin; Antonio Monge-Vega; Dinorah Gambino
Journal:  J Inorg Biochem       Date:  2005-02       Impact factor: 4.155

7.  Calorimetric studies of the interaction between the insulin-enhancing drug candidate bis(maltolato)oxovanadium(IV) (BMOV) and human serum apo-transferrin.

Authors:  Abdol-Khalegh Bordbar; A Louise Creagh; Fakhrossadat Mohammadi; Charles A Haynes; Chris Orvig
Journal:  J Inorg Biochem       Date:  2008-10-17       Impact factor: 4.155

8.  A novel vanadyl complex with a polypyridyl DNA intercalator as ligand: a potential anti-protozoa and anti-tumor agent.

Authors:  Julio Benítez; Lucía Guggeri; Isabel Tomaz; João Costa Pessoa; Virtudes Moreno; Julia Lorenzo; Francesc X Avilés; Beatriz Garat; Dinorah Gambino
Journal:  J Inorg Biochem       Date:  2009-07-24       Impact factor: 4.155

Review 9.  Vanadium in cancer treatment.

Authors:  Angelos M Evangelou
Journal:  Crit Rev Oncol Hematol       Date:  2002-06       Impact factor: 6.312

10.  Transport of the anti-diabetic VO2+ complexes formed by pyrone derivatives in the blood serum.

Authors:  Daniele Sanna; Linda Bíró; Péter Buglyó; Giovanni Micera; Eugenio Garribba
Journal:  J Inorg Biochem       Date:  2012-05-11       Impact factor: 4.155

View more
  4 in total

1.  Molecular dynamics simulations of plutonium binding and its decorporation from the binding-cleft of human serum transferrin.

Authors:  Lokpati Mishra; Mahesh Sundararajan; Tusar Bandyopadhyay
Journal:  J Biol Inorg Chem       Date:  2020-01-24       Impact factor: 3.358

Review 2.  Vanadium: History, chemistry, interactions with α-amino acids and potential therapeutic applications.

Authors:  Edgar Del Carpio; Lino Hernández; Carlos Ciangherotti; Valentina Villalobos Coa; Lissette Jiménez; Vito Lubes; Giuseppe Lubes
Journal:  Coord Chem Rev       Date:  2018-06-21       Impact factor: 22.315

3.  ESI-MS Study of the Interaction of Potential Oxidovanadium(IV) Drugs and Amavadin with Model Proteins.

Authors:  Valeria Ugone; Daniele Sanna; Giuseppe Sciortino; Debbie C Crans; Eugenio Garribba
Journal:  Inorg Chem       Date:  2020-06-25       Impact factor: 5.165

4.  Many-Body Study of Iron(III)-Bound Human Serum Transferrin.

Authors:  Hovan Lee; Cedric Weber; Edward B Linscott
Journal:  J Phys Chem Lett       Date:  2022-05-12       Impact factor: 6.888

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.